In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic fragment Nangibotide | Natural peptide Vasoactive intestinal peptide (VIP, aviptadil) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic fragment | Natural peptide | |
| Area | Immune and antimicrobial | Immune and antimicrobial | |
| Evidence | |||
| Amount of evidence | 140 | 887 (plus 505 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 18 (17 in people) | 29 (23 in people) | |
| Status | |||
| Approval | Not recorded | ||
| Sport (WADA) | |||
| Registered trials | 1 · 1 active | 15 · 1 active8 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Nangibotide | Vasoactive intestinal peptide (VIP, aviptadil) |
|---|---|---|
| Receptor activity and mechanismRespiratory | 231157 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
| Heart functionCardiovascular | 1515 | 4918247 |
|---|
| Respiratory functionRespiratory | 11 | 4318817 |
|---|
| Vascular functionCardiovascular | 651 | 7173727 |
|---|
| Adverse eventsWhole body | 99 | 18144 |
|---|
| PharmacokineticsPharmacology | 77 | 17710 |
|---|
| Intensive care and hospital outcomesWhole body | 761 | 99 |
|---|
| Blood pressureCardiovascular | 33 | 288182 |
|---|
| Inflammation markersRespiratory | 22211 | 212712 |
|---|
| Immune responseRespiratory | 8233 | 301722 |
|---|
| MortalityWhole body | 862 | 44 |
|---|
| Bone and jointMusculoskeletal | 853 | 312 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Nangibotide | Vasoactive intestinal peptide (VIP, aviptadil) |
|---|---|---|
| Intensive care and hospital outcomesRespiratoryCompared as: value in the arm that got the peptide, in days | No comparable result 6 randomized-trial results measure it in another way or another unit. | 7.8 days Time to discharge Placebo: 10 days n = 802025 |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | No comparable result 9 randomized-trial results measure it in another way or another unit. | 63% Primary safety outcome Placebo: 56% 3 daysn = 4612023 |
| MortalityWhole bodyCompared as: difference from placebo, in % | 12.1% Adjusted absolute mortality improvement Dose studied: 1.0 mg/kg/hn = 2192023 |
No comparable result
6 randomized-trial results measure it in another way or another unit.
7.8 days
Time to discharge
Placebo: 10 days
n = 802025
No comparable result
4 randomized-trial results measure it in another way or another unit.
No comparable result
9 randomized-trial results measure it in another way or another unit.
63%
Primary safety outcome
Placebo: 56%
3 daysn = 4612023
12.1%
Adjusted absolute mortality improvement
Dose studied: 1.0 mg/kg/hn = 2192023
No comparable result
4 randomized-trial results measure it in another way or another unit.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)
Inotrem355 participants13 Nov 2019 to est. 9 May 2023
Shock, Septic
Top 3 of 15 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
National Institute of Allergy and Infectious Diseases (NIAID)473 participants20 Apr 2021 to 20 Nov 2022
Covid19
National Institute of Allergy and Infectious Diseases (NIAID)471 participants20 Apr 2021 to 20 Nov 2022
Covid19
APR Applied Pharma Research s.a.203 participants15 May 2020 to 22 Feb 2021
Critical COVID-19 With Respiratory Failure · Acute Respiratory Distress Syndrome (ARDS) · Corona Virus Infection · Acute Lung Injury
8 more mention it but do not test it. They only measure it or name it in their text.